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We show that atypical PKC, which plays a critical role in the
establishment and maintenance of epithelial cell polarity, is
genomically amplified and overexpressed in serous epithelial ovar-
ian cancers. Furthermore, PKC protein is markedly increased or
mislocalized in all serous ovarian cancers. An increased PKC DNA
copy number is associated with decreased progression-free sur-
vival in serous epithelial ovarian cancers. In a Drosophila in vivo
epithelial tissue model, overexpression of persistently active atyp-
ical PKC results in defects in apical–basal polarity, increased Cyclin
E protein expression, and increased proliferation. Similar to the
Drosophila model, increased PKC proteins levels are associated
with increased Cyclin E protein expression and proliferation in
ovarian cancers. In nonserous ovarian cancers, increased PKC
protein levels, particularly in the presence of Cyclin E, are associ-
ated with markedly decreased overall survival. These results im-
plicate PKC as a potential oncogene in ovarian cancer regulating
epithelial cell polarity and proliferation and suggest that PKC is a
novel target for therapy.
epithelial cell polarity  proliferation
Ovarian cancer remains the leading cause of death fromgynecological malignancy among women in the U.S. (1).
The prognosis for advanced disease has not improved signifi-
cantly, suggesting that an improved understanding of the genetic
aberrations in ovarian cancer is critical to identifying better ways
to prevent, diagnose and treat this frequently fatal disease.
Atypical PKC (aPKC)  is located at 3q26.2, the most frequent
genomic amplicon in ovarian cancer (2), as indicated by array
comparative genomic hybridization (3). PKC is the sole catalytic
component of the Par3–Par6–aPKC complex, which plays a critical
role in the establishment andmaintenance of epithelial cell polarity,
tight junctions, and adherens junctions (4). InDrosophila, loss of the
polarity-determining tumor suppressors Scribble, Discs large, and
Lethal giant larvae contributes to tumor formation (5, 6). Impor-
tantly, loss of apical–basal cell polarity is required for epithelial–
mesenchymal transition (EMT), which is a critical step in cellular
motility and invasiveness (7). Loss of polarity also allows several
growth factors and receptors, which are normally compartmental-
ized because of tight junctions in polarized cells, to mediate
autocrine cell activation (8, 9). Thus, deregulation of PKC, the key
catalytic regulator of the formation and maintenance of polarity
and tight junctions, could contribute to the pathophysiology of
ovarian cancer.
Materials and Methods
Patients. Primary ovarian cancer patient samples (80% tumor
on histology), normal ovarian epithelium, and information were
collected under Institutional Review Board-approved Health
Insurance Portability and Accountability Act (HIPAA)- com-
pliant protocols at M. D. Anderson Cancer Center; University of
Toronto; Duke University; University of California, San Fran-
cisco; and Northwestern University.
Normal ovarian epithelium was obtained by directly scraping
ovarian epithelial cells into RNAlater (Ambion, Austin, TX). At
least 90% of cells isolated are of epithelial origin, as determined
by staining for cytokeratins.
High-Density Array Comparative Genomic Hybridization. Bacterial
artificial chromosome (BAC) DNA arrays were prepared and
probed as described (3) by using 200 contiguous BAC clones
covering 28 Mbp of 3q26-q28 centered on 3q26.2 at PKC.
RNA Quantification. Total RNA was extracted from tissue samples
by using TRIzol reagent (Invitrogen) according to the manu-
facturer’s instructions. mRNA levels were determined by Taq-
Man RT-PCR, using 40 cycles with -actin as reference.
Tissue Microarray Construction and Immunohistochemical Analysis.
Tissue microarrays were generated from paraffin-embedded
specimens of 441 cases of epithelial ovarian cancers with out-
comes and 85 additional specimens reflecting specific histotypes
of tumors at the University of Texas M. D. Anderson Cancer
Center. Slides were stained with anti-PKC (1:100, BD Trans-
duction Laboratories), anti-phospho-PKC (1:300, Abcam, Cam-
bridge, MA), anti-Cyclin E (HE-12 1:100, Santa Cruz Biotech-
nology), anti-E cadherin (1:100, BD Transduction
Laboratories), or anti-Ki67 (1:100, DakoCytomation, Carpinte-
ria, CA) antibodies. Staining was detected by streptavidin–
biotin–peroxidase and 3,3-diaminobenzidine. E cadherin was
detected by using FITC-labeled goat anti-mouse antibody
(Caltag, Burlingame, CA). Nuclei were stained with DAPI
(Sigma). We defined the Ki67 labeling index with 15% as high
and15% as low. Cyclin E was judged to be positive when10%
of nuclei stained. Anti-PKC was shown to be specific for PKC
by Western blotting of tumor tissue and COS7 cells transfected
with plasmids encoding PKC or PKC. The anti-phospho-PKC
antibody crossreacts with phospho-PKC according to the man-
ufacturer. However, ovarian cancers contain little to no detect-
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able PKC; thus, the anti-phospho-PKC antibody detects pri-
marily phospho-PKC.
Western Blot Analysis. Western blot analysis was performed as
described (10) by using Cyclin E, PKC, and Actin monoclonal
antibodies (Roche Molecular Biochemicals).
Fly Stocks. Drosophila atypical protein kinase M (DaPKM) in
UAS-DaPKM starts at Met-223 within the hinge region of
Drosophila PKC (DaPKC) (11). Persistently active rat PKC
(rPKC*) with a 5-aa deletion within the pseudosubstrate do-
main (residues 117–121) (12) was cloned into the XbaI site of
pUAST (13). Eight independent transgenic rPKC* lines gave a
similar phenotype. Other stocks were yw; GMR-GAL4, UAS-
GFP andGMR-GAL4 andGMR-hid-Ala-5 and UAS-p35 and yw;
dpp-GAL4, UAS-GFPTM6B.
Immunohistochemistry and Cell Death Assay of Drosophila Imaginal
Discs. Imaginal discs were stained as described (14) with the
following antibodies (dilutions): rabbit anti-PKC C20 (1:500;
Santa Cruz Biotechnology), rat anti-Elav (1:60; Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City), rabbit
anti-Patj (1:400; K. Choi, Baylor College of Medicine, Houston),
and mouse anti-BrdUrd (1:50; Becton Dickinson). Donkey Fab
fragment secondary antibodies were from Jackson ImmunoRe-
search. BrdUrd incorporation was for 1 h (14). Apoptosis
(TUNEL) was detected by using an in situ cell death detection
kit (Roche Applied Science, Indianapolis).
Statistical Analysis. Experiment results were analyzed with 2 test
of independence, Spearman correlation, Kruskal–Wallis test,
Mann–Whitney test, or Wilcoxon rank sum test, as appropriate.
Survival rates were calculated by using Kaplan–Meier analysis
(15). Differences in survival were analyzed by using the log-rank
test and univariate and multivariate Cox proportional hazards
models (16). All tests were two-tailed and were considered
statistically significant if P  0.05.
Results
Amplification of PKC Contributes to Increased PKC Expression and
Reduced Progression-Free Survival in Ovarian Cancer. By using a
high-density chromosome 3q array comparative genomic hybrid-
ization contig, the PKC DNA copy number was increased in
70% of serous epithelial ovarian cancers (Fig. 1a) and was
associated with a significantly shorter progression-free survival
duration (P 0.0006) (Fig. 1b). Similarly, PKCRNA levels were
increased in 80% of serous epithelial ovarian cancers, as
compared with normal ovarian surface epithelial cells (17, 18),
with the magnitude and frequency of PKCRNA increases being
higher in serous epithelial ovarian cancers than in other histo-
types of ovarian cancer and tumor lineages (Fig. 1c). As indicated
by TaqMan RT-PCR, PKC mRNA levels were markedly in-
creased in advanced (Stage IIIIV) ovarian cancers as compared
with normal ovarian surface epithelial cells, benign epithelial
tumors, or early (Stage III) ovarian cancers (Fig. 6 a and b,
which is published as supporting information on the PNAS web
site). Although the magnitude of the RNA increase was consis-
tently greater than the DNA copy number increase, PKC DNA
and RNA levels were correlated in serous epithelial ovarian
cancers (P  0.05, Fig. 6c), indicating that the increase in DNA
copy number contributes to the elevated RNA levels.
Ectopic Expression of Persistently Active aPKC in Drosophila Imaginal
Eye Discs Results in Loss of Cell Polarity.We evaluated the potential
mechanisms by which increased levels of PKC contribute to
transformation of epithelial cells by overexpressing two persistently
active forms of aPKC in epithelial tissues in the model organism
Drosophila: (i) DaPKM (11), which produces a naturally occurring
active form of DaPKC lacking the Par6-binding site (19) and the
aPKC pseudosubstrate site (20), and (ii) rPKC*, with a 5-aa
deletion within the pseudosubstrate site (12). There is only one
aPKC in Drosophila (DaPKC), allowing these two constructs to
Fig. 1. Amplification of the PKC gene and increased PKC RNA expression in
ovarian cancer. (a) Array comparative genomic hybridization analysis of PKC
DNA copy number in 235 Grade 3 and Stage III or IV serous epithelial ovarian
cancer samples (log2 ratio of cancer patient DNA to normal DNA). (b) Increase
in PKC DNA copy number is associated with a decreased progression-free
survival period. For patients where followup information was available, pro-
gression-free survival in patients with high PKC DNA copy number (n  26)
was significantly worse (P  0.0006) than in patients with low PKC copy
number (n 46) (cutoff at 0.37 log2). Vertical lines indicate censored patients,
i.e., patients for whom no further followup information was available after
the indicated time points. (c) Microarray analysis ofPKCgene expression. Two
different studies using Affymetrix DNA microarray analysis (17, 18) show
marked elevation of PKC gene expression in serous epithelial ovarian cancers
as compared with pooled (I) and normal ovarian (II) epithelium.
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represent the effects of PKC, the aPKC amplified in ovarian
cancer. Endogenous DaPKC is an apical cell polarity marker in
wild-type eye imaginal discs (21) (Fig. 2 a, d, g, and j). BothDaPKM
(Fig. 2 b, e, h, and k) and rPKC* (Fig. 2 c, f, i, and l) were
mislocalized in transgenic eye discs. Polarization of endogenous
Pals-associated tight junction protein (Patj) (22, 23), an apical cell
polarity marker (Fig. 2 m and p), was decreased in DaPKM-
transgenic eye discs (Fig. 2 n and q) and completely lost in
rPKC*-transgenic eye discs (Fig. 2 o and r). Thus, overexpression
of persistently active aPKC is sufficient to induce defects in apical–
basal polarity in Drosophila epithelial cells.
Persistently Active aPKC Induces Proliferation, Increases in Cyclin E,
and Disorganization of Cellular Architecture Without Increasing Apo-
ptosis in Drosophila Epithelial Cells. In wild-type eye discs, cell
proliferation, as indicated by BrdUrd incorporation, was ran-
Fig. 3. Ectopic expression of persistently active aPKC in third-instar larval eye
andwingdiscs inducesproliferation,disorganization,andup-regulationofCyclin
E protein. (a–c) Wild-type (a) and DaPKM-transgenic (b) or rPKC*-transgenic (c)
eye discs under control of the GMR-GAL4 driver (45), stained for BrdUrd incor-
poration. (d–f) Wild-type (d) and DaPKM-transgenic (e) or rPKC*-transgenic (f)
eye discs stained for neuronal marker Elav. (g–i) Overlay of BrdUrd and Elav
staining. White boxes indicate the location of higher-magnification views in j–l.
(m–o) Cyclin E expression: wild-type (m), and DaPKM-transgenic (n) or rPKC*-
transgenic (o) eye discs, stained for Cyclin E. (p–r) Wing discs: wild-type (p) and
DaPKM-transgenic (q) or rPKC*-transgenic (r) wing discs under control of the
dpp-GAL4 driver, resulting in transgene expression in a band of cells along the
anteroposterior compartment boundary of the wing, stained for BrdUrd incor-
poration. The confocal images shown ina–landp–rare extended field views, and
the images in m–o are views of single focal planes. Arrowheads indicate the
morphogenetic furrow. Arrows indicate the second mitotic wave. Anterior is to
the left for all eye discs.
Fig. 2. Ectopic expression of persistently active aPKC in Drosophila third-
instar larval eye discs causes defects in apical–basal polarity and tissue archi-
tecture. Transgenes were expressed in cells posterior to the morphogenetic
furrow by using the UAS-GAL4 two-component system (13). Wild-type (a, d, g,
and j), DaPKM-transgenic (b, e, h, and k), and rPKC*-transgenic (c, f, i, and l)
eye discs stained for aPKCaPKM (red) and Elav (green) are shown. Boxes ina–c
indicate areas of magnified views in g–l. Wild-type eye disc (m and p),
DaPKM-transgenic eye disc (n and q), and rPKC*-transgenic eye disc (o and r)
stained for Pals-associated tight junction protein (Patj) are shown. Lines in
planar views (m–o) indicate location of cross-section views in p–r. Anterior is
to the left for all discs.
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domly distributed anterior to the morphogenetic furrow, a
dorsal–ventral groove marking the boundary of photoreceptor
differentiation, arrested in G1 in the furrow (Fig. 3a, arrowhead)
and underwent an additional round of cell division referred to as
the second mitotic wave posterior to the furrow (Fig. 3a, arrow).
Posterior to the second mitotic wave, cells cease proliferation
and differentiate into photoreceptor, cone, pigment, and bristle
cells (24). Only rare BrdUrd-positive cells were found in the
posterior area of wild-type eye discs, where photoreceptor cells
express the neuronal marker Elav (25) (Fig. 3 a and g). In
contrast to wild-type eye discs, DaPKM- or rPKC*-transgenic
eye discs showed massive incorporation of BrdUrd posterior to
the second mitotic wave (Fig. 3 b and c, asterisk). DaPKM-
transgenic (Fig. 3 e and h) and rPKC*-transgenic (Fig. 3 f and
i) eye discs, in contrast to wild-type eye discs (Fig. 3 d and g),
displayed pronounced changes in the spacing, patterning, and
size of photoreceptor clusters posterior to the second mitotic
wave. In DaPKM-transgenic and rPKC*-transgenic eye discs
(Fig. 3 k and l), the BrdUrd-positive DNA-synthesizing cells
posterior to the second mitotic wave were Elav-negative. Thus,
the DNA-synthesizing cells either have lost Elav expression or
are nonneural cells. Increased proliferation induced by DaPKM
or rPKC* was not limited to imaginal eye discs, because there
was a dramatic increase in the number of BrdUrd-incorporating
cells in transgenic (Fig. 3 q and r), as compared with wild-type
(Fig. 3p) wing discs.
In imaginal disc cells, Cyclin E is limiting for S-phase initiation
(26). Concurrent with the increase in proliferation, Cyclin E
protein levels were dramatically increased in DaPKM-transgenic
and rPKC*-transgenic eye disc cells posterior to the second
mitotic wave (Fig. 3 n and o), as compared with wild-type eye
discs (Fig. 3m). Coexpression of the Cyclin E antagonist Dacapo,
which is the Drosophila p21CIPp27Kip1 cyclin-dependent kinase
inhibitor ortholog, results in amelioration of the DaPKM
rPKC* phenotype (data not shown), indicating a critical role of
Cyclin E in mediating the DaPKMrPKC* phenotype.
DaPKM-transgenic and rPKC*-transgenic eye discs did not
show an increase in apoptosis by TUNEL using expression of
activated Drosophila proaptotic Hid as a positive control (Fig. 7,
which is published as supporting information on the PNAS web
site, and data not shown). Furthermore, expression of p35, a
pan-caspase inhibitor, failed to alter the morphological effects of
overexpression of DaPKM and rPKC* in eye discs (data not
presented). Thus, although aPKC increases cell cycle progres-
sion, it does not increase apoptosis inDrosophila epithelial tissue.
PKC Protein Is Mislocalized and Overexpressed in Ovarian Cancer.
Informed by the studies in Drosophila, we assessed whether
increased PKC DNA and RNA levels in ovarian cancer cells
were associated with changes in polarity, Cyclin E expression,
and cell proliferation and, furthermore, whether this constella-
tion of effects contributes to the prognosis of epithelial ovarian
cancer.
PKC was present at the apical membrane and absent from the
basal membrane in normal ovarian surface epithelial cells and in
benign serous and mucinous cysts (Fig. 4 a, b, and f ). In serous
low malignant potential (LMP), although PKC levels were
modestly elevated (Fig. 8, which is published as supporting
information on the PNAS web site), membrane localization of
PKC was lost in 85% (Fig. 4c). As with mRNA levels, PKC
protein was increased in 85% of low- and high-grade serous
epithelial ovarian cancers, as compared with normal ovarian
Fig. 4. Histotype- and progression-dependent mislocalization and overexpression of PKC and phospho-PKC. (a–k) Immunohistochemical staining of PKC (P
 0.0036). Normal ovarian surface epithelial cells (a) and serous (b) and mucinous ( f) inclusion cysts showing apical PKC (arrows) are shown. Serous LMP (c), low-
(d) and high-grade (e) serous, and mucinous (h) carcinoma with cytoplasmic PKC, with loss of apical PKC are also shown. (g) Mucinous LMP showing regions
of apical PKC (arrow) or cytoplasmic PKC with loss of apical localization (arrowhead). (i and j) Clear cell (i) and low-grade (j) endometrioid carcinomas showing
cytoplasmic PKCwith areas of cell membrane PKC (arrows). (k) High-grade endometrioid carcinoma with cytoplasmic PKC. (l–o) Immunohistochemical staining
of phospho-PKC. (l–n) Serous inclusion cyst (l) and low-grade (m) and high-grade (n) serous carcinoma with cytoplasmic PKC. (o) High-grade serous carcinoma
with membranous PKC. Arbitrary optic density units SD for antiphospho-PKC samples are 79 3 for normal ovarian epithelium, 71.3 5.7 for serous cysts,
123.6  22.4 for low-grade serous carcinomas, and 107  22.8 for high-grade serous carcinomas (P  0.0036).
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surface epithelial cells (Table 1, which is published as supporting
information on the PNAS web site). Strikingly, apical membrane
location of PKC was abrogated in all (322) serous epithelial
ovarian cancers analyzed (Fig. 4 d and e). Similar to the mRNA
data, PKC protein was increased in a smaller percentage of
nonserous ovarian cancers (50%) than serous cancers (Table 1).
In contrast to serous LMP, PKC was absent from the membrane
in only 20% of mucinous LMP tumors. However, PKC no longer
localized to the membrane in 90% of mucinous carcinomas,
80–90% of clear cell carcinomas, 60–70% of low-grade endo-
metrioid ovarian carcinomas, and all high-grade endometrioid
ovarian carcinomas (Fig. 4 f–k). As expected from RNA analysis
(Fig. 6 a–c), PKC protein levels were significantly associated
with histotype (P  0.00001), stage (P  0.00001), and grade
(P  0.01) (Table 1).
The pattern of localization of the adherens junction marker
E-cadherin (27) was concordant with that of PKC being localized
to the apical–lateral membrane domain in serous and mucinous
cysts andmucinous LMP,while being predominantly cytoplasmic in
serous LMP as well as in low- and high-grade serous and mucinous
carcinomas (Fig. 9, which is published as supporting information on
the PNAS web site). This is compatible with the effects of PKC
overexpression in ovarian cancer contributing to aberrant E-
cadherin and adherens junction function.
Activated PKC Is Overexpressed and Mislocalized in the Cytoplasm in
Ovarian Cancer. Activated PKC levels, assessed by using an anti-
body recognizing the autophosphorylation site of PKC and thus
reflecting PKC activity, are increased in ovarian carcinomas as
compared with normal ovarian surface epithelial cells and cysts
(P  0.0036) (Fig. 4 l–o). A small group of serous high-grade
carcinomas demonstrated membranous localization of phospho-
PKC (20376) (Fig. 4o); however, it was mislocalized in all other
conditions (Fig. 4 l–n). Similar to total PKC, PKC activity is an
indicator of outcomes with 70245 (28.6%) patients with low
phospho-PKC protein levels being alive at 5 years vs. 858 (13.8%)
patients with high phospho-PKC levels (P  0.03).
High Levels of PKC and Cyclin E Protein Contribute to Outcomes in
Nonserous Epithelial Ovarian Cancer. Based on the effect of the
aPKC transgenes on Drosophila epithelia, we assessed the inter-
actions among PKC, Cyclin E, and Ki67 and their contribution
to patient outcomes. Elevated PKC protein levels were associ-
ated with elevated levels of low molecular weight (LMW) forms
of Cyclin E (10) protein in 16 of 18 ovarian cancer patient
samples (Fig. 5a). In tissue microarrays, PKC correlated with
Cyclin E (using an antibody that recognizes all forms of Cyclin
E because antibodies specific to LMW Cyclin E are not avail-
able) protein levels (P 0.01) and proliferation (Ki67 levels, P
0.02). Ki67 and Cyclin E levels were also highly correlated (P 
0.0001). Four transcriptional profiling data sets comprising a
total of 215 ovarian cancer patient samples of mixed histology,
grade, and stage demonstrated a direct Spearman correlation
[P 0.001 (in-house data set), P 0.002 (17), P 0.05 (28), and
P  0.05 (29)], with a positive linear regression on three of the
four data sets [P 0.01 (in house), and P 0.05 (28, 29)]. PKC
levels, alone or in combination with Cyclin E levels, were
indicative of prognosis in nonserous epithelial ovarian cancers
(Fig. 5 b and c). Indeed, nonserous epithelial ovarian cancers
with low levels of both Cyclin E and PKC demonstrated a
remarkably good prognosis with almost 90% of patients being
alive at 5 years, whereas patients with high levels of both
demonstrated a poor prognosis with 20% alive at 5 years.
Univariate Cox proportional hazards models (16) showed that
patients with nonserous tumors with high PKC levels had a
higher likelihood of death (Table 2, which is published as
supporting information on the PNAS web site). This finding is
compatible with a previous small study demonstrating an asso-
ciation of PKC protein levels with outcome (30) and with studies
indicating an association of Cyclin E with outcome (10, 31). In
amultivariate model that included both PKC and Cyclin E levels
as independent variables, the association between overall sur-
vival and PKC levels remained significant in nonserous epithe-
lial tumors (Table 2). PKC was either mislocalized or overex-
pressed in all serous epithelial ovarian cancers, suggesting that
the processes normally regulated by PKC, likely apical–basal
polarity, are functionally aberrant in all serous epithelial ovarian
cancers. Indeed, supporting this contention, PKC levels were
not predictive of outcomes in serous epithelial ovarian cancers.
Discussion
We show that, in ovarian cancer patients, high PKC levels correlate
with defects in polarity, increased Cyclin E protein expression, and
increased proliferation. aPKC levelsmust apparently bemaintained
within critical boundaries for the establishment andmaintenance of
Fig. 5. Association of increased PKC and Cyclin E protein levels with
decreased survival in ovarian cancer patients. (a) Cyclin E and PKC levels in 18
high-grade and Stage III or IV serous ovarian epithelial tumors were analyzed
by Western blotting. EL-1 represents full-length Cyclin E, and EL-2–6 represent
LWM forms of Cyclin E. Samples 1–10 and 11–18 are from independent gels
with two extraneous lanes removed from gel 2. (b) Increase in PKC protein
level is associated with a decreased overall survival period in nonserous
epithelial ovarian cancer patients. (c) Increases in both PKC and Cyclin E
protein levels are associated with a decreased overall survival period in
nonserous epithelial ovarian cancer patients. Vertical lines indicate censored
patients.
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epithelial cell polarity, because both increase and loss of aPKC
result in defects in apical–basal polarity inDrosophila (our data and
refs. 32 and 33). Although the tumor suppressorsDiscs large, Lethal
giant larvae, and Scribble regulate apical–basal polarity, cell sur-
vival, and cellular proliferation (34, 35), loss of polarity is not
sufficient to induce cellular proliferation, at least in part because of
altered cell survival (32, 36). In contrast, overexpression of activated
aPKC was sufficient to induce cellular proliferation in Drosophila
epithelial tissues, potentially because of a failure of overexpressed
aPKC to induce apoptosis.
Many receptors are located in different compartments and are
separated by tight junctions or specifically localized to and activated
at junctional complexes (8, 9). Under conditions such as wounding,
where polarity and junctional complexes are abrogated, an auto-
crine interaction between growth factors and receptors contributes
to wound healing. In ovarian cancer, the disruption of polarity as a
consequence of overexpression and activation of PKC could result
in aberrant autocrine signaling. Furthermore, polarity defects could
cause mislocalization of intracellular signal transduction compo-
nents (37). Thus, a loss of polarity due to overexpression of PKC
could directly lead to increased proliferation contributing to tu-
morigenesis. Loss of E-cadherin, which plays a pivotal role in
epithelial organization and suppresses aberrant proliferation (7,
38), from adherens junctions because of aberrant PKC activity and
subsequent loss of polarity could also contribute to increased
proliferation. Indeed, E-cadherin is mislocalized and associated
with outcomes in ovarian cancer (39, 40). The tumor suppressor
Disabled-2, originally identified in Drosophila, mediates basement
membrane attachment of ovarian epithelial cells, thus ensuring
correct positioning, emphasizing the critical importance of main-
tenance of polarity (41).
The Drosophila in vivo epithelial model system informed
subsequent human studies demonstrating an interaction be-
tween PKC and Cyclin E levels and patient outcome. Because
overexpression of aPKC is sufficient to increase Cyclin E protein
in Drosophila, up-regulation of PKC may play a causal role in
Cyclin E deregulation in ovarian cancer. Strikingly, LMW forms
of Cyclin E and PKC were coordinately up-regulated in ovarian
cancers. Because the LMW forms of Cyclin E are hyperactive,
associated with resistance to p21 and p27 and with genomic
instability (10, 42, 43), the interaction between PKC and LMW
Cyclin E may play a role in the initiation and progression of
ovarian cancer as well as in patient outcomes. Although in-
creased Cyclin E levels had been shown to be associated with a
worsened outcome in ovarian cancers (10, 31), concurrent
analysis of Cyclin E and PKC levels provides a superior pre-
dictor of outcome in nonserous ovarian cancers than either
alone, indicating an interaction between these two determinants.
Cyclin E levels are increased in a number of ovarian cancers
without elevated PKC, suggesting that additional mechanisms
must regulate Cyclin E protein levels. Once again, a convergence
of studies in Drosophila and human ovarian cancer may be
informative, because Archipelago, which has been demonstrated
to regulate Cyclin E degradation in Drosophila, is mutationally
inactivated in a fraction of ovarian cancers (44).
PKC protein levels and the incidence of PKC mislocalization
increase with stage and grade, suggesting that PKC plays a role in
tumor progression. PKC contributes to tumor aggressiveness,
because high PKC protein levels are associated with reduced
survival. Taken together, it appears that PKC plays a role in the
pathophysiology of ovarian cancer contributing to tumor progres-
sion and aggressiveness. Thus, PKC should be explored as amarker
of prognosis, in particular aggressiveness of ovarian cancers, and
should be evaluated as a potential therapeutic target.
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